About this trial
The purpose of this study is to assess the efficacy and safety of single injection dose of AURN001 compared with placebo in adult participants with corneal edema secondary to corneal endothelial dysfunction.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Have corneal edema secondary to corneal endothelial dysfunction, requiring surgery (full- or partial-thickness endothelial keratoplasty)
BCVA between 65 ETDRS letters (approximate 20/50 Snellen equivalent) and 5 ETDRS letters (approximate 20/800 Snellen equivalent)
Be pseudophakic with PCIOL
Disqualifiers
Have progressive corneal dystrophies or degenerations
Have visually significant corneal or other ocular pathologies
Trial design
Parallel
Treatments tested in this trial
Combination Product: AURN001 + Y-27632
DrugAURN001 will be injected to the anterior chamber of the eye.
Placebo
Other interventionPlacebo control will be injected to the anterior chamber of the eye.
Treatment groups
Trial outcomes
Primary outcomes
Percentage of participants who achieve a ≥ 15-letter improvement (3-line gain) from baseline in Best Corrected Visual Acuity (BCVA) at Month 6
Secondary outcomes
Change from baseline in non-contact Central Corneal Thickness (CCT) at Month 6
Change from baseline in BCVA at Month 6
Sponsors and contacts
Click on the lead sponsor to view all of their trials.